Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 2

2(33.3%)

Phase 4

1(16.7%)

6Total

N/A(3)

Phase 2(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07066865Not ApplicableCompleted

Evaluation of the Safety and Effectiveness of omniLenz in Patient With Ocular Graft vs Host Disease

Role: lead

NCT05720715Phase 4Completed

Clinical Outcomes of Cyclosporine Eye Drops in Management of Herpetic Keratitis

Role: lead

NCT06539663Phase 2Completed

The Role of OmniLenz® in the Treatment of Small Corneal Perforations Secondary to Exposure Keratitis in ICU Patients

Role: lead

NCT05771012Not ApplicableCompleted

Topical Cyclosporin A 0.05% Eye Drops for Management of Symptomatic Acquired Punctal Stenosis. A Prospective, Controlled Clinical Study.

Role: lead

NCT05618522Not ApplicableCompleted

Omnigen in Acute Chemical Eye Injuries

Role: lead

NCT04637633Phase 2Completed

Topical Cyclosporine-A for Management of Epiphora

Role: lead

All 6 trials loaded